CRGDyk-targeted PAMAM nanoparticles for synergistic phototherapy/chemotherapy targeting of melanoma

Rui Duan

doi:10.1117/12.2660567

6 December 2022 CRGDyk-targeted PAMAM nanoparticles for synergistic phototherapy/chemotherapy targeting of melanoma

Rui Duan

Proceedings Volume 12458, International Conference on Biomedical and Intelligent Systems (IC-BIS 2022); 124580U (2022) https://doi.org/10.1117/12.2660567
Event: International Conference on Biomedical and Intelligent Systems, 2022, Chengdu, China

Abstract

Temozolomide (TMZ) and indocyanine green (ICG) are relatively effective drugs for cancer treatment. TMZ can effectively cross the barrier between blood and brain, while ICG has a high thermal conversion rate, but they also have disadvantages such as easy decomposition in vivo and poor targeting. In order to address the shortcomings of these two drugs and to improve their stability and targeting in vivo, as well as to further enhance their efficacy, I will use PAMAM nanoparticles to encapsulate TMZ and ICG and target the tumour-targeting peptide cRGDyk as a synergistic therapy, and conduct relevant experimental validation.

Citation Download Citation

Rui Duan "CRGDyk-targeted PAMAM nanoparticles for synergistic phototherapy/chemotherapy targeting of melanoma", Proc. SPIE 12458, International Conference on Biomedical and Intelligent Systems (IC-BIS 2022), 124580U (6 December 2022); https://doi.org/10.1117/12.2660567

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available